Clinical outcomes of GLP-1 receptor agonists VS placebo among patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis.
GLP-1 receptor agonists reduce hospitalization from heart failure in patients with obesity or diabetes, addressing a major gap in treatment options for this condition.
Meta-analysis of 3 RCTs in 1,463 HFpEF patients demonstrates that GLP-1 receptor agonists significantly reduce HF hospitalization events and improve quality-of-life metrics versus placebo, without a significant mortality reduction in this pooled analysis. The morbidity benefit supports GLP-1 RA use in HFpEF patients with obesity/diabetes comorbidity, an important unmet clinical need given limited treatment options in this population.
What the study was
- Study design
- Systematic review and meta-analysis of randomised controlled trials
- Category
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Validated
- Journal
- Egypt Heart J
Why it surfaced
First meta-analysis of GLP-1 RA specifically in HFpEF; timely given expanded GLP-1 RA approvals; Atma Jaya Catholic University Jakarta; limited number of RCTs (3) and moderate journal (Egypt Heart J) are caveats. Findings align with STEP-HFpEF and SELECT trial data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.